Patient with Hypertriglyceridemia, Type 2 Diabetes, and Chronic Kidney Disease Treated with Atorvastatin and Omega-3 Fatty Acid Ethyl Esters

Vasilios G Athyros1, * , Dimitri P Mikhailidis2
1 Atherosclerosis Unit, Department of Internal Medicine, School of Medicine, Aristotelian University of Thessaloniki, Greece
2 Department of Clinical Biochemistry (Vascular Disease Prevention Clinics), Royal Free Hospital campus, University College London Medical School, University College London (UCL), London, UK

Article Metrics

CrossRef Citations:
Total Statistics:

Full-Text HTML Views: 690
Abstract HTML Views: 661
PDF Downloads: 261
Total Views/Downloads: 1612
Unique Statistics:

Full-Text HTML Views: 436
Abstract HTML Views: 394
PDF Downloads: 192
Total Views/Downloads: 1022

© Athyros and Mikhailidis; Licensee Bentham Open.

open-access license: This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.

* Address correspondence to this author at the 15 Marmara St., Thessaloniki, 55132, Greece; Tel: +30 2310 892606; Fax: +30 2310 454237; E-mail:


This is a case report that describes a 67-year-old woman with mixed hyperlipidemia and diabetic nephropathy. She was initially prescribed a combination of simvastatin plus gemfibrozil by her general practitioner (GP). When referred to our cardiovascular unit, we further diagnosed the patient to have mixed hyperlipidemia and rhabdomyolysis. Because of concerns with her chronic kidney disease (CKD), we temporarily stopped all her drug treatments and started insulin treatment for her type 2 diabetes (T2D). A month later when her T2D was stabilised, we prescribed atorvastatin and an omega-3 fatty acid ethyl ester supplement to treat her hypertriglyceridemia. Within two months her blood lipids were within the recommended range. In patients with stage 3–5 CKD, it is not advisable to prescribe the fibrate gemfibrozil, particularly in combination with a statin that is metabolised predominantly in the kidneys. To minimise adverse events without compromise on efficacy, we used a combination of omega-3 fatty acid ethyl esters, which are not metabolised in the kidneys, with a statin that is minimally metabolised in the kidneys for the treatment of her hyperlipidemia.

Keywords: Hypertriglyceridemia, statin, omega-3 fatty acid ethyl esters, type 2 diabetes..


We describe a 67-year-old woman with mixed hyperlipidemia and diabetic nephropathy. She was initially prescribed a combination of simvastatin plus gemfibrozil by her General Practitioner (GP) and was then referred to our unit with rhabdomyolysis (Table 1). Drugs were temporarily discontinued and she only received insulin. Current evidence suggests that statins can improve the glomerular filtration rate (GFR) or delay GFR decline in patients with type 2 diabetes (T2DM) [1]. However, the patient’s general practitioner had initially prescribed a combination of simvastatin plus gemfibrozil: both of these drugs are substantially metabolized by the kidneys. As the patient already had stage 3 chronic kidney disease (CKD; estimated glomerular filtration rate 30 - 59 ml/min/1.73m2), which is frequently seen in diabetic subjects [1, 2], this resulted in the accumulation of both drugs in the blood and she developed rhabdomyolysis. Rhabdomyolysis associated with the simvastatin + gemfibrozil combination, is an adverse effect seen even in patients with normal kidney function. To control the hyperlipidemia, we changed her treatment to an omega-3 fatty acid ethyl ester supplement (Omacor®) in combination with atorvastatin; both drugs have negligible renal metabolism [3-5].

Table 1.

Laboratory Measurements

November 23, 2011 February 21, 2012 March 22, 2012 May 16, 2012
CK (IU/L) 145 3,250 157 133
AST (IU/L) 24 135 28 20
ALT (IU/L) 26 43 30 23
LDH (IU/L) NA 1,485 312 253
Glomerular filtration rate mL/min/1.73m2 NA 41 44 44
Serum potassium (mmol/L) 4.1 6.9 4.7 4.2
Blood platelet count (/µL) NA 272,000 254,000 261,000

ALT = alanine aminotransferase; AST = aspartate aminotransferase; CK = creatine kinase; LDH = lactate dehydrogenase.


A 67-year-old woman presented to her general practitioner on November 23, 2011. Five years previously, she had been diagnosed with T2DM, and was taking sitagliptin (100 mg/day). Her condition had now progressed to diabetic nephropathy with a reduced GFR of 41 mL/min/1.73m2. To help control her T2DM, she had been restricting her intake of carbohydrates and animal fat, with no restrictions on her dietary protein. She weighed 70 kg [body mass index (BMI) = 27.3 Kg/m2). Electrocardiography findings were normal, and the patient had no obvious symptoms or family history of cardiovascular disease (CVD). She was a non-smoker and did little physical activity. In addition to sitagliptin, hergeneral practitioner began treatment with simvastatin (40 mg/day) and gemfibrozil (1200 mg/day). She was also taking quinapril (20 mg/day) and aspirin (100 mg/day).

We first saw this patient in our hospital cardiovascular unit on February 21, 2012. In addition to T2DM and CKD, we diagnosed the patient had mixed hyperlipidemia (Fig. 1) and rhabdomyolysis (diffuse myalgia, low fever, fatigue, dark urine). Her heart rate was 92 bpm, while her left ventricular end-diastolic diameter (43 mm) and left ventricular ejection fraction (63%) were normal. Laboratory tests showed she had raised activities of serum creatine kinase (CK), aspartate aminotransferase (AST), and lactate dehydrogenase (LDH) (Table 1). Because of our concerns with her CKD, we temporarily discontinued all her drugs and started insulin treatment for her T2DM.

Fig. (1).

Fasting blood lipid levels throughout treatment.

A month later, her serum activities of CK, AST, and LDH were within the reference range (Table 1). We restarted sitagliptin (100 mg/day) and quinapril (20 mg/day), and changed her statin to atorvastatin (40 mg/day). We also prescribed an omega-3 fatty acid ethyl ester supplement (Omacor® 4 g/day, Abbott Laboratories (Hellas) SA, Athens, Greece) specifically to treat her hypertriglyceridemia. We also recommended lifestyle changes for the patient: she was started on the National Cholesterol Education Program Step II diet, which is reported to help lower blood total cholesterol and low-density lipoprotein cholesterol concentrations [6, 7], and she was set a goal of walking for 60 min at least 5 days/week.

By May 16, 2012 her blood lipids were within the recommended range according to our departmental guidelines (LDL-C <100 mg/dl and TGs <150 mg/dl – Fig. 1). She had lost 2 kg in weight (BMI 26.7 Kg/m2) since November 2011, her blood pressure had reduced from 140/80 to 125/75 mmHg, and her heart rate was now 78 bpm. After 2 months of treatment with atorvastatin and omega-3 fatty acid ethyl ester supplementation, her GFR was 44 mL/min/1.73m2. There were no side effects. As of June 2012, she has T2DM (HbA1c = 6.8%) and stage 3 CKD, with no abnormalities in her blood lipid profile. No additional treatments are currently planned.


This overweight patient with diabetic nephropathy developed rhabdomyolysis, presumably as a side effect of the simvastatin + gemfibrozil combination; the combination of simvastatin + sitagliptin might have also played a role [8]. Age and DM are also associated with statin-induced rhabdomyolysis and may have played a role in this case, however the simvastatin + gemfibrozil combination is the main suspect [9]. In patients with stage 3 - 5 CKD, it is not advisable to prescribe the fibrate gemfibrozil, particularly in combination with a statin such as simvastatin that is predominantly metabolized by the kidneys; this is a very high risk regimen [10].

Patients with stage 3 - 5 CKD make up a substantial proportion of high-risk patients with cardiovascular disease (30% of coronary heart disease patients and 20 - 40% of diabetic patients) [10-12]. Patients with both T2DM and CKD are at particularly high risk of cardiovascular disease [13-17] and it is imperative to monitor their GFR. This need is reinforced by the fact that diabetic patients have very frequently both hypertriglyceridemia and CKD and thus physicians should be aware of the recommended treatment in such patients [18]. The recommended treatment for patients with diabetic nephropathy is to reduce the risk or slow the progression of nephropathy and optimize glucose control [5, 18-23]. Where required, the treatment plan may need to be adjusted over time to reduce or manage adverse events. Data from post-hoc analyses of statin trials indicate a beneficial effect of statin therapy on cardiovascular disease outcomes in patients with stages 2 and 3 CKD; the benefit was particularly marked in patients with both CKD and diabetes [24-26]. A further complication of the disease management plan, most patients with stage 3 - 5 CKD also have mixed dyslipidemia [23, 24].

Our aim for this patient was firstly to control her T2DM [23], to protect her from the cardiorenal syndrome [21, 22] and then to reduce her blood lipid levels down to the guideline range [23]. A meta-analysis of 26 clinical trials involving over 25,000 patients showed that statins are effective in the treatment of dyslipidemia in non-dialysis patients with CKD [26]. Furthermore, the authors concluded that statins significantly reduced the risk of all-cause and cardiovascular mortality in this patient group.

Omega-3 fatty acid ethyl ester supplementation is an effective and well-tolerated treatment that can be combined with statins to further reduce blood triglyceride levels [27-30]. Recent European guidelines propose that the combination of omega-3 fatty acid ethyl esters, which are not metabolized in the kidneys, with a statin that is minimally metabolized in the kidneys (e.g. atorvastatin, fluvastatin) is effective and well tolerated in the treatment of mixed hyperlipidemia [23].


In combination with atorvastatin, an omega-3 fatty acid ethyl ester supplement was effective and well-tolerated treatment for this patient’s mixed dyslipidemia.


The author(s) confirm that this article content has no conflicts of interest.


The authors acknowledge the editorial assistance provided by Adelphi Communications Ltd, UK, which was supported by an unrestricted educational grant from Abbott Products Operations AG, Allschwil, Switzerland.

Writing assistance for this paper was supported by an unrestricted educational grant from Abbott Products Operations AG, Allschwil, Switzerland.


[1] Athyros VG, Mitsiou EK, Tziomalos K, Karagiannis A, Mikhailidis DP. Impact of managing atherogenic dyslipidemia on cardiovascular outcome across different stages of diabetic nephropathy Expert Opin Pharmacother 2010; 11: 723-30.
[2] Athyros VG, Papageorgiou AA, Elisaf M, Mikhailidis DP. GREACE Study Collaborative. Group. Statins and renal function in patients with diabetes mellitus Curr Med Res Opin 2003; 19: 615-7.
[3] Athyros VG, Karagiannis A, Kakafika A, Elisaf M, Mikhailidis DP. Statins and renal function. Is the compound and dose making a difference? Nephrol Dial Transplant 2007; 22: 963-4.
[4] Liberopoulos EN, Mikhailidis DP, Athyros VG, Elisaf MS. The effect of cholesterol-lowering treatment on renal function Am J Kidney Dis 2006; 47: 561-0.
[5] Tziomalos K, Athyros VG, Karagiannis A, Mikhailidis DP. Omega-3 fatty acids: how can they be used in secondary prevention? Curr Atheroscler Rep 2008; 10: 510-7.
[6] Schaefer EJ, Lichtenstein AH, Lamon-Fava S, et al. Effects of National Cholesterol Education Program Step 2 diets relatively high or relatively low in fish-derived fatty acids on plasma lipoproteins in middle-aged and elderly subjects Am J Clin Nutr 1996; 63: 234-41.
[7] Sun Z, Welty FK, Dolnikowski GG, Lichtenstein AH, Schaefer EJ. Effects of a National Cholesterol Education Program Step II Diet on apolipoprotein A-IV metabolism within triacylglycerol-rich lipoproteins and plasma Am J Clin Nutr 2001; 74: 308-14.
[8] Boucher BJ. Renal failure and rhabdomyolysis associated with sitagliptin and simvastatin use. But what about the amiodarone? Diabet Med 2009; 26: 192-3.
[9] Bellosta S, Paoletti R, Corsini A. Safety of statins: focus on clinical pharmacokinetics and drug interactions Circulation 2004; 109(III): 50-7.
[10] Athyros VG, Katsiki N, Karagiannis A, Mikhailidis DP. Stage of chronic kidney disease and severity of coronary heart disease manifestation Expert Opin Pharmacother 2012; 13: 457-60.
[11] Athyros VG, Hatzitolios AI, Karagiannis A, et al. For the imperative collaborative group. improving the implementation of current guidelines for the management of major coronary heart disease risk factors by multifactorial intervention. the imperative renal analysis Arch Med Sci 2011; 7: 984-2.
[12] Athyros VG, Karagiannis A, Ganotakis ES. Assessing the treatment effect in metabolic syndrome without perceptible diabetes (ATTEMPT) collaborative group. association between the changes in renal function and serum uric acid levels during multifactorial intervention and clinical outcome in patients with metabolic syndrome. A post hoc analysis of the ATTEMPT study Curr Med Res Opin 2011; 27: 1659-68.
[13] Efstratiadis G, Tziomalos K, Mikhailidis DP, Athyros VG, Hatzitolios A. Atherogenesis in renal patients: a model of vascular disease? Curr Vasc Pharmacol 2008; 6: 93-107.
[14] Athyros VG, Kakafika AI, Papageorgiou AA. Statin-induced increase in HDL-C and renal function in coronary heart disease patients Open Cardiovasc Med J 2007; 1: 8-14.
[15] Athyros VG, Karagiannis A, Katsiki N, Mikhailidis DP. Statins in patients with renal dysfunction Am J Cardiol 2012; 109: 1537.
[16] Athyros VG, Katsiki N, Karagiannis A, Mikhailidis DP. Should chronic kidney disease be considered as a coronary heart disease equivalent? Curr Vasc Pharmacol 2012; 10: 374-7.
[17] Tziomalos K, Ganotakis ES, Gazi IF, Nair DR, Mikhailidis DP. Kidney Function and estimated vascular risk in patients with primary dyslipidemia Open Cardiovasc Med J 2009; 3: 57-68.
[18] Athyros VG, Tziomalos K, Karagiannis A, Mikhailidis DP. Dyslipidaemia of obesity, metabolic syndrome and type 2 diabetes mellitus: the case for residual risk reduction after statin treatment Open Cardiovasc Med J 2011; 5: 24-34.
[19] Athyros VG, Karagiannis A, Liberopoulos EN, Elisaf M, Mikhailidis DP. Statin treatment may be beneficial to both the kidneys and the heart Perit Dial Int 2007; 27: 215-6.
[20] Mitsiou EK, Athyros VG, Karagiannis A, Mikhailidis DP. Is there a role for hypolipidaemic drug therapy in the prevention or treatment of microvascular complications of diabetes? Open Cardiovasc Med J 2012; 6: 28-32.
[21] Fabbian F, Pala M, Giorgi A De, et al. Clinical features of cardiorenal syndrome in a cohort of consecutive patients admitted to an internal medicine ward Open Cardiovasc Med J 2011; 5: 220-5.
[22] Athyros VG, Katsiki N, Tziomalos K, Karagiannis A. Preventing cardio-renal syndrome rather than treating it: could statins play a role? Open Cardiovasc Med J 2011; 5: 226-30.
[23] Reiner , Catapano AL, De Backer G, et al. ESC/EAS Guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) Eur Heart J 2011; 32: 1769-818.
[24] Diabetes and Chronic Kidney Disease Work Group. KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease Am J Kidney Dis 2007; 49: S13-9.
[25] Athyros VG, Mikhailidis DP, Papageorgiou AA, et al. The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease.A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study J Clin Pathol 2004; 57: 728-34.
[26] Navaneethan SD, Pansini F, Perkovic V, et al. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis Cochrane Database Syst Rev 2009; CD007784.
[27] Chan DC, Watts GF, Mori TA, Barrett PH, Beilin LJ, Redgrave TG. Factorial study of the effects of atorvastatin and fish oil on dyslipidaemia in visceral obesity Eur J Clin Invest 2002; 32: 429-36.
[28] Durrington PN, Bhatnagar D, Mackness MI, et al. An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridaemia Heart 2001; 85: 544-8.
[29] Chan DC, Watts GF, Barrett PH, Beilin LJ, Redgrave TG, Mori TA. Regulatory effects of HMG CoA reductase inhibitor and fish oils on apolipoprotein B-100 kinetics in insulin-resistant obese male subjects with dyslipidemia Diabetes 2002; 51: 2377-86.
[30] Davidson MH, Stein EA, Bays HE, et al. Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study Clin Ther 2007; 29: 1354-67.